- Home
- OCS vs CMPX Comparison
OCS vs CMPX Comparison
Compare OCS & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCS
- CMPX
- Stock Information
- Founded
- OCS 2003
- CMPX 2014
- Country
- OCS Switzerland
- CMPX United States
- Employees
- OCS N/A
- CMPX N/A
- Industry
- OCS Biotechnology: Pharmaceutical Preparations
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- OCS Health Care
- CMPX Health Care
- Exchange
- OCS Nasdaq
- CMPX Nasdaq
- Market Cap
- OCS 869.8M
- CMPX 730.9M
- IPO Year
- OCS N/A
- CMPX N/A
- Fundamental
- Price
- OCS $21.71
- CMPX $4.04
- Analyst Decision
- OCS Strong Buy
- CMPX Strong Buy
- Analyst Count
- OCS 4
- CMPX 7
- Target Price
- OCS $41.00
- CMPX $14.71
- AVG Volume (30 Days)
- OCS 77.9K
- CMPX 1.7M
- Earning Date
- OCS 11-06-2025
- CMPX 11-11-2025
- Dividend Yield
- OCS N/A
- CMPX N/A
- EPS Growth
- OCS N/A
- CMPX N/A
- EPS
- OCS N/A
- CMPX N/A
- Revenue
- OCS $960,668.00
- CMPX N/A
- Revenue This Year
- OCS $36.75
- CMPX N/A
- Revenue Next Year
- OCS $1,261.53
- CMPX N/A
- P/E Ratio
- OCS N/A
- CMPX N/A
- Revenue Growth
- OCS N/A
- CMPX N/A
- 52 Week Low
- OCS $14.00
- CMPX $1.27
- 52 Week High
- OCS $23.08
- CMPX $4.86
- Technical
- Relative Strength Index (RSI)
- OCS 76.98
- CMPX 54.17
- Support Level
- OCS $21.19
- CMPX $3.31
- Resistance Level
- OCS $21.79
- CMPX $4.86
- Average True Range (ATR)
- OCS 0.66
- CMPX 0.29
- MACD
- OCS 0.28
- CMPX 0.02
- Stochastic Oscillator
- OCS 93.88
- CMPX 46.74
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.